Serina Therapeutics
25 hedge funds and large institutions have $2.48M invested in Serina Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 4 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
9% more funds holding
Funds holding: 23 → 25 (+2)
0.36% more ownership
Funds ownership: 4.14% → 4.5% (+0.36%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $2.54M → $2.48M (-$69.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$156K |
| 2 |
LW
Linscomb Wealth
Houston,
Texas
|
+$100K |
| 3 |
State Street
Boston,
Massachusetts
|
+$67.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.4K |
| 5 |
Citigroup
New York
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$81.5K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$21.9K |
| 3 |
BC
Broadwood Capital
New York
|
-$10.8K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$10.5K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$234 |
SER Hedge Fund Activity: Q3 2025 in Review
25 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q3 2025, worth a combined $2.48M — down 2.7% from $2.54M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SER positions and 4 closed out — a net gain of 2 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $156K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $81.5K sold.
- 25 institutional investors held Serina Therapeutics (SER) as of Q3 2025, up from 23 in Q2 2025.
- Funds reported $2.48M of Serina Therapeutics stock for Q3 2025, down 2.7% quarter-over-quarter.
- 6 funds opened new Serina Therapeutics positions in Q3 2025 and 4 closed out, a net change of +2 holders.
- The largest Serina Therapeutics buyer in Q3 2025 was Vanguard Group, an estimated $156K added.
- The largest Serina Therapeutics seller in Q3 2025 was Susquehanna International Group, an estimated $81.5K sold.
Based on aggregated 13F filings for Q3 2025.